keyword
MENU ▼
Read by QxMD icon Read
search

Mantle cell lymphoma

keyword
https://www.readbyqxmd.com/read/28541116/imbruvica-%C3%A2-%C3%A2-ibrutinib-patient-support-programme-for-chronic-lymphocytic-leukaemia-and-mantle-cell-lymphoma
#1
Vidhya Murthy, Susan Weaving, Shankara Paneesha
Single-agent ibrutinib is an effective therapy for three types of non-Hodgkin lymphoma: chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma, both in relapsed and refractory cases and as a frontline treatment; relapsed and refractory mantle cell lymphoma; and Waldenstrom's macroglobulinaemia in patients who have been treated previously with a different medication. This novel agent has changed the landscape for the aforementioned three subtypes of lymphoma therapies as an oral alternative to traditional chemoimmunotherapy...
May 25, 2017: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/28536906/current-status-of-bruton-s-tyrosine-kinase-inhibitor-development-and-use-in-b-cell-malignancies
#2
REVIEW
Andrew Aw, Jennifer R Brown
The B-cell receptor (BCR) pathway plays an important role in the survival, proliferation and trafficking of cancer cells in a variety of B-cell malignancies. Recently, a number of agents have been developed to target various components of the BCR pathway. One such target is Bruton's tyrosine kinase (BTK), a Tec family kinase member found near the cell membrane that is involved in upstream BCR signaling. The biological function of BTK in several B-cell lymphoid malignancies has led to the development of the oral BTK inhibitor ibrutinib...
May 23, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28536895/autologous-stem-cell-transplantation-asct-in-patients-with-mantle-cell-lymphoma-a-retrospective-study-of-the-spanish-lymphoma-group-geltamo
#3
A García-Noblejas, J Cannata-Ortiz, E Conde, E González Barca, N Gutiérrez, R Rojas, M J Vidal, M J Ramírez, A Jiménez-Ubieto, J C García-Ruiz, J M Sancho, A López, P Ríos Rull, S Novelli, C Albo, G Debén, A López-Guillermo, C Nicolás, S González de Villambrosia, S Mercadal, A Martín García-Sancho, R Arranz
Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively...
May 24, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28533307/sox11-promotes-tumor-protective-microenvironment-interactions-through-cxcr4-and-fak-regulation-in-mantle-cell-lymphoma
#4
Patricia Balsas, Jara Palomero, Álvaro Eguileor, Marta Leonor Rodriguez, Maria Carmela Vegliante, Ester Planas-Rigol, Marta Sureda-Gómez, Maria C Cid, Elias Campo, Virginia Amador
SOX11 overexpression in Mantle Cell Lymphoma (MCL) has been associated with more aggresive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly known. Here, we demonstrate that SOX11 binds to regulatory regions of two important genes for microenvironment-signals in cancer, (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase (FAK)). Moreover, SOX11-positive xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared to their SOX11-negative counterparts...
May 22, 2017: Blood
https://www.readbyqxmd.com/read/28529032/synergistic-cytotoxicity-of-lenalidomide-and-dexamethasone-in-mantle-cell-lymphoma-via-cereblon-dependent-targeting-of-the-il-6-stat3-pi3k-axis
#5
Jiexian Ma, Kefei Wu, Weiya Bai, Xiaoxian Cui, Yan Chen, Youhua Xie, Yanhui Xie
At our center, relapsed mantle cell lymphoma (MCL) can be treated with maintenance therapy composed of consecutive low-dose lenalidomide and short-term, high-dose dexamethasone (LD regimen), which achieves good responses (longer overall survival and progression-free survival) and low toxicity. Cereblon is probably targeted by both lenalidomide and dexamethasone, which leads to synergistic cytotoxicity in MCL by inhibiting the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3), phosphatidylinositol 3-kinase (PI3K)/AKT and AKT2/Forkhead box O3 (FOXO3A)/BCL2-like 11 (BIM) pathways...
May 10, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28503306/the-drive-to-generate-multiple-forms-of-oncogenic-cyclin-d1-transcripts-in-mantle-cell-lymphoma
#6
EDITORIAL
Chioniso Patience Masamha
Alternative polyadenylation is a rapidly emerging form of gene regulation, which in its simplest form, enables the generation of mRNA transcripts that code for the same protein but have 3'UTRs of different lengths and regulatory content. For oncogenes, shorter 3'UTRs would be preferred as a mechanism to evade miRNA regulation. The shortening of the 3'UTR of cyclin D1 in mantle cell lymphoma offers provocative insights into this process. Patient samples have revealed that 3'UTR shortening may occur due to mutations, or translocations that result in the generation of a chimeric 3'UTR...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28495928/cyclin-d1-negative-blastoid-mantle-cell-lymphoma-exhibiting-cleaved-to-bilobated-cytomorphology
#7
Huan-You Wang, Alexey Hodkoff
No abstract text is available yet for this article.
May 11, 2017: Blood
https://www.readbyqxmd.com/read/28480764/novel-agents-in-mantle-cell-lymphoma
#8
David Tucker, Simon Rule
Mantle cell lymphoma (MCL) usually takes an aggressive clinical course and carries a poor prognosis. Recently, progress has been made in the treatment of MCL including the development of a number of novel agents which target intracellular pathways and the extracellular microenvironment. These agents have transformed the landscape of available therapeutic options. Areas covered: The current literature on the novel agents which currently hold a licence for the treatment of MCL in the context of front-line therapy and in the relapsed/refractory setting is summarized...
June 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28473415/triple-hit-blastoid-mantle-cell-lymphoma-presenting-like-acute-leukemia
#9
Jie Xu, Shaoying Li
No abstract text is available yet for this article.
May 4, 2017: Blood
https://www.readbyqxmd.com/read/28468797/selective-inhibition-of-nuclear-export-with-selinexor-in-patients-with-non-hodgkin-s-lymphoma
#10
John Kuruvilla, Michael Savona, Rachid Baz, Morten Mau-Sorensen, Nashat Gabrail, Ramiro Garzon, Richard Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian Flinn, Meagan Jacoby, T J Unger, Jean R Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez
Patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B cell lymphoma (DLBCL), Richter's transformation, mantle cell lymphoma (MCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) were enrolled...
May 3, 2017: Blood
https://www.readbyqxmd.com/read/28466437/role-of-sox11-and-genetic-events-cooperating-with-cyclin-d1-in-mantle-cell-lymphoma
#11
REVIEW
Sílvia Beà, Virginia Amador
Mantle cell lymphoma (MCL) is an aggressive lymphoid neoplasm, incurable with current therapies. The t(11;14)(q13;q32) involving cyclin D1 is considered the first oncogenic hit found in virtually all MCLs. However, additional secondary genomic alterations are essential for complete transformation. MCLs are genetically very unstable with several genetic alterations associated with its high proliferative behavior involving several oncogenic pathways. Furthermore, SOX11 is overexpressed in the majority of conventional MCLs (cMCL), including cyclin D1-negative cases, but absent in non-nodal leukemic MCL with indolent clinical behavior (nnMCL)...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28457696/numerous-ontogenetic-roads-to-mantle-cell-lymphoma-immunogenetic-and-immunohistochemical-evidence
#12
Evi Pouliou, Aliki Xochelli, George Kanellis, Evangelia Stalika, Lesley-Ann Sutton, Alba Navarro, Andreas Agathangelidis, Kypros Dimosthenous, Achilles Anagnostopoulos, Efstratios Patsouris, Penelope Korkolopoulou, Christer Sundstrom, Paolo Ghia, Maurilio Ponzoni, Birgitta Sander, Elias Campo, Richard Rosenquist, Anastasia Hadzidimitriou, Kostas Stamatopoulos, Theodora Papadaki
To obtain insight into the ontogeny of mantle cell lymphoma (MCL), we assessed 206 patients from a morphological, immunohistochemical, and immunogenetic perspective. Our series included nodal (n = 151), extranodal (n = 28), and primary splenic (n = 27) MCL cases. Skewing of the immunoglobulin heavy variable (IGHV) gene repertoire was noted, with only four IGHV genes accounting for 46% of cases and approximately 70% of cases (107/154) bearing an imprint of somatic hypermutation (SHM) ranging from minimal to pronounced...
April 27, 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/28456850/influence-of-body-mass-index-on-survival-in-indolent-and-mantle-cell-lymphomas-analysis-of-the-stil-nhl1-trial
#13
Lukas Weiss, Thomas Melchardt, Alexander Egle, Georg Hopfinger, Hubert Hackl, Richard Greil, Juergen Barth, Mathias Rummel
Obesity is a well-known risk factor for the development of cancer, but its influence on the course of disease is still controversial. We investigated the influence of body mass index (BMI) on overall survival (OS) in 502 patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma in a subgroup analysis of the StiL (Study Group Indolent Lymphomas) NHL1 trial. We defined a cut-off of 22.55 kg/m(2) by ROC calculation and Youden Index analysis and stratified patients into "low BMI" and "high BMI". Five-year OS was significantly longer in the high BMI group (82...
April 30, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28454248/primary-bone-mantle-cell-lymphomas-with-multiple-vertebral-compression-fractures-a-case-report
#14
Peng Yang, Jun Lin, Hao Liu, Hao Shen, Hui-Lin Yang
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma. Patients with MCL generally present with extensive lymphadenopathy and extranodal involvement. To the best of our knowledge, no cases of primary bone MCL with multiple vertebral compression fractures have been reported in the literature thus far. The current study reports the case of a 75-year-old Chinese male patient presenting with lower back pain for 1 year. B symptoms were not observed in the patient's medical history. X-ray revealed osteoporosis, and mixed osteolytic and osteosclerotic lesions in the T10 and L1 vertebrae with decreased height...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28451951/gastrointestinal-mantle-cell-lymphoma-with-isolated-mass-and-multiple-lymphomatous-polyposis-report-of-two-cases
#15
Shunichi Yanai, Shotaro Nakamura, Satoko Yamaguchi, Keisuke Kawasaki, Kazuyuki Ishida, Tamotsu Sugai, Junji Umeno, Motohiro Esaki, Takayuki Matsumoto
We herein report two patients with mantle cell lymphoma (MCL), who had isolated mass and multiple lymphomatous polyposis (MLP) in the gastrointestinal tract. In case 1, esophagogastroduodenoscopy revealed a protruding mass in the duodenum and double-balloon endoscopy disclosed numerous polypoid lesions in the ileum. Case 2 had polyposis in the duodenum and a large mass-forming lesion in the ascending colon. Based on the histologic and immunohistochemical findings of the biopsy specimens, the diagnosis of MCL was made in both patients...
April 27, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/28434928/hypercvad-chemotherapy-in-mantle-cell-lymphoma-patients-is-associated-with-higher-rates-of-hematopoietic-progenitor-cell-mobilization-failure-despite-plerixafor-rescue
#16
Amandeep Salhotra, Yuan Shan, Ni-Chun Tsai, James F Sanchez, Ibrahim Aldoss, Haris Ali, Tanya Paris, Ricardo Spielberger, Thai M Cao, Auayporn Nademanee, Stephen J Forman, Robert Chen
Induction regimens for mantle cell lymphoma (MCL) can be categorized into highly intensive ones containing cytarabine and less intense regimens such as R (rituximab) CHOP or R-bendamustine. Prior publications have shown R-hyperCVAD can be associated with stem cell mobilization failures. However, those studies did not include the use of plerixafor as rescue for stem cell mobilization failure. We examined our database of 181 consecutive MCL patients from 2005 to 2015 who received upfront therapy with either R-hyperCVAD or less intense chemotherapy (R-bendamustine and R-CHOP only) regimens to assess impact of frontline chemotherapy on collection of hematopoietic cell progenitors prior to autologous stem cell transplant (ASCT)...
April 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28429312/sox11-regulates-the-pro-apoptosis-signal-pathway-and-predicts-a-favorable-prognosis-of-mantle-cell-lymphoma
#17
Wenjuan Yang, Yanying Wang, Zhen Yu, Zengjun Li, Gang An, Wei Liu, Rui Lv, Liping Ma, Shuhua Yi, Lugui Qiu
Sex-determining region Y-box 11 (SOX11) is an important diagnostic marker in mantle cell lymphoma (MCL). However, the direct oncogenic mechanisms and downstream effector pathways implicated in SOX11-driven transformation remain poorly understood. In the present study, we analyzed SOX11 expression in B-NHL, and used lentivirus-mediated RNA interference targeting SOX11 to investigate the resulting changes in cellular processes and the underlying mechanisms in MCL cell lines. We found that patients with higher SOX11 expression have superior overall survival (OS) and progression-free survival (PFS) compared to those with lower SOX11 expression...
April 20, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28423727/paclitaxel-synergizes-with-exposure-time-adjusted-cd22-targeting-immunotoxins-against-b-cell-malignancies
#18
Fabian Müller, Stephanie Stookey, Tyler Cunningham, Ira Pastan
CD22-targeted recombinant immunotoxins (rIT) are active in hairy cell leukemia or acute lymphoblastic leukemia (ALL), but not in mantle cell lymphoma (MCL) patients. The goal was to enhance rIT efficacy in vivo and to define a strong combination treatment. Activity of Moxetumomab pasudotox (Moxe) and LR combined with paclitaxel was tested against MCL cell lines in vitro and as bolus doses or continuous infusion in xenograft models. In the KOPN-8 ALL xenograft, Moxe or paclitaxel alone was active, but all mice died from leukemia; when combined, 60% of the mice achieved a sustained complete remission...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28422443/role-of-cd200-in-differential-diagnosis-of-mature-b-cell-neoplasm
#19
K Rahman, P Kumar, R Gupta, M K Singh, S Nityanand
INTRODUCTION: CD 200 is a type I immunoglobulin super family membrane glycoprotein, which is expressed in various mature B-cell neoplasm (MBN). This study aimed at analyzing the expression pattern of CD200 by flow cytometry immunophenotyping (FCI) and to evaluate its utility in narrowing down the differential diagnosis of MBN, particularly in low-grade lymphomas. METHODS: A total of 160 samples were evaluated by FCI over a period of 2 years (July 2014-June 2016), by a panel of antibodies including CD200...
April 19, 2017: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/28419413/long-term-outcomes-secondary-malignancies-and-stem-cell-collection-following-bendamustine-in-patients-with-previously-treated-non-hodgkin-lymphoma
#20
Peter Martin, Zhengming Chen, Bruce D Cheson, Katherine S Robinson, Michael Williams, Saurabh A Rajguru, Jonathan W Friedberg, Richard H van der Jagt, Ann S LaCasce, Robin Joyce, Kristen N Ganjoo, Nancy L Bartlett, Bernard Lemieux, Ari VanderWalde, Jordan Herst, Jeffrey Szer, Michael H Bar, Fernando Cabanillas, Anthony J Dodds, Paul G Montgomery, Bryn Pressnail, Tricia Ellis, Mitchell R Smith, John P Leonard
Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39-84), and patients had received a median of 3 prior therapies. The histologies included grades 1-2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2)...
April 17, 2017: British Journal of Haematology
keyword
keyword
10129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"